
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
“We need to do a better job of delineating the value our industry provides in addressing medical problems. Health economics allows us to better quantify the benefits of our solutions to patient outcomes, health-related quality of life, and individuals involved in patient care.” Listen to the Podcast for more coverage.






